Dogwood Therapeutics Inc. Ordinary Shares DWTX 深 滬
等待開盤 09-12 09:30:00 美东时间
4.8968
+0.037
+0.76%
華盛通- 最 高4.8968
- 今 開4.84
- 成交量 2339股
- 最 低 4.84
- 昨 收 4.86
- 總市值 935.83万
- 52周最高 29.28
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.62
- 委 比 -12.79%
- 總股本 191.11万
- 歷史最高 417.75
- 量 比 0.37
- 振 幅 1.17%
- 歷史最低 1.87
- 每 手 1
- 風險率 2.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Dogwood Therapeutics (Nasdaq: DWTX) will participate in the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025, at the Lotte New York Palace Hotel. CEO Greg Duncan will join Sean Lee for a fireside chat on September 5, 2025, available on-demand at 7:00am ET. The presentation and replay can be accessed via the investor relations section of Dogwood's website. Duncan will be available for one-on-one meetings during the co...
09-03 13:15
Dogwood Therapeutics Q2 EPS $(1.99) Misses $(1.90) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate of $(1.90) by 4.74 percent. This is a 73.04 percent decrease over losses of $(1.15) per share
08-13 21:00
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
Dogwood Therapeutics announced enrollment of 52 patients in its Halneuron® Phase 2b trial for chemotherapy-induced neuropathic pain (CINP), with interim data expected in Q4 2025. The low discontinuation rate of 5.8% due to adverse events suggests good tolerability. The company reported a cash balance of $13.4 million, providing operational runway through Q1 2026. Research and development expenses increased by $2.2 million due to clinical trial co...
08-13 13:00
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Dogwood Therapeutics announced enrollment of the first 50 patients in its Phase 2b trial for Halneuron® to treat chemotherapy-induced neuropathic pain (CINP). The trial remains on track for interim data analysis in Q4 2025, with plans to enroll up to 100 patients. Early data shows a low 6% discontinuation rate due to adverse events, indicating good tolerability. Halneuron®'s unique targeting of NaV1.7 sodium channels differentiates it from other ...
08-07 17:08
Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Dogwood Therapeutics announces second-quarter 2025 financial results will be reported on August 13. The biotech company focuses on developing new treatments for pain and fatigue-related disorders. Its pipeline includes a non-opioid analgesic program, Halneuron, targeting pain reduction in cancer and chemotherapy-induced neuropathy, with Q4 2025 interim data expected. Additionally, its antiviral program, IMC-1 and IMC-2, aims to treat fibromyalgia...
08-06 13:15
Dogwood Therapeutics Approves CFO Salary Increase
Dogwood Therapeutics ( ($DWTX) ) has provided an announcement. On June 27, 2025...
07-03 04:28
Dogwood Therapeutics Approves Equity Plan Amendment
Dogwood Therapeutics ( ($DWTX) ) just unveiled an announcement. On June 18, 202...
06-24 22:49
Sidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Sidoti Events, LLC, an affilia...
06-10 19:30
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
Dogwood Therapeutics的首席执行官Greg Duncan将在2025年6月11日至12日的Sidoti Small-Cap Virtual Conference上进行公司概述，包括其Halneuron和其他产品线的最新进展。会议时间为美国东部时间6月11日上午9:15，可在此注册：https://sidoti.zoom.us/webinar/register/WN_C6ACWY1kTXGa0eBkFbVd0w。此会议还包括与Duncan的一对一会谈安排。Dogwood专注于开发治疗疼痛和疲劳相关疾病的新型药物。其Halneuron是一种非阿片类镇痛剂，而IMC-1和IMC-2则为抗病毒药物，针对包括纤维肌痛和长新冠在内的疾病。Halneuron的II期临床试验数据预计于2025年底公布。请注意，Dogwood的候选药物尚未被证明有效。如需更多信息，请访问www.dwtx.com。
06-03 13:15
